We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert: FDA Needs Predictability in REMS Development
Expert: FDA Needs Predictability in REMS Development
January 23, 2009
Drugmakers need guidance from the FDA to clarify when the agency would require companies to develop risk evaluation and mitigation strategies (REMS), an expert told WDL.